drugset / Trial / NCT07139067
Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors
Phase 1
Recruiting
10 enrolled
Peking University
Yingkai Saiwei（Beijing）Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.
Timeline
- Start
- 2025-04-27
- Primary completion
- 2026-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YK1101 | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
Indications
No indication recorded.